916 related articles for article (PubMed ID: 23395275)
1. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis.
Yuan J; Zhang R; Yang Z; Lee J; Liu Y; Tian J; Qin X; Ren Z; Ding H; Chen Q; Mao C; Tang J
Eur Urol; 2013 May; 63(5):902-12. PubMed ID: 23395275
[TBL] [Abstract][Full Text] [Related]
2. A return to normal erectile function with tadalafil once daily after an incomplete response to as-needed PDE5 inhibitor therapy.
Kim ED; Seftel AD; Goldfischer ER; Ni X; Burns PR
J Sex Med; 2014 Mar; 11(3):820-30. PubMed ID: 23841532
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy of tadalafil once daily in men with erectile dysfunction who demonstrated previous partial responses to as-needed sildenafil, tadalafil, or vardenafil.
Kim E; Seftel A; Goldfischer E; Baygani S; Burns P
Curr Med Res Opin; 2015 Feb; 31(2):379-89. PubMed ID: 25455432
[TBL] [Abstract][Full Text] [Related]
4. SOP conservative (medical and mechanical) treatment of erectile dysfunction.
Porst H; Burnett A; Brock G; Ghanem H; Giuliano F; Glina S; Hellstrom W; Martin-Morales A; Salonia A; Sharlip I;
J Sex Med; 2013 Jan; 10(1):130-71. PubMed ID: 23343170
[TBL] [Abstract][Full Text] [Related]
5. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability.
Wang R; Burnett AL; Heller WH; Omori K; Kotera J; Kikkawa K; Yee S; Day WW; DiDonato K; Peterson CA
J Sex Med; 2012 Aug; 9(8):2122-9. PubMed ID: 22759639
[TBL] [Abstract][Full Text] [Related]
6. Ten years of phosphodiesterase type 5 inhibitors in spinal cord injured patients.
Lombardi G; Macchiarella A; Cecconi F; Del Popolo G
J Sex Med; 2009 May; 6(5):1248-58. PubMed ID: 19210710
[TBL] [Abstract][Full Text] [Related]
7. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
Gacci M; Corona G; Salvi M; Vignozzi L; McVary KT; Kaplan SA; Roehrborn CG; Serni S; Mirone V; Carini M; Maggi M
Eur Urol; 2012 May; 61(5):994-1003. PubMed ID: 22405510
[TBL] [Abstract][Full Text] [Related]
8. Treating erectile dysfunction and central neurological diseases with oral phosphodiesterase type 5 inhibitors. Review of the literature.
Lombardi G; Nelli F; Celso M; Mencarini M; Del Popolo G
J Sex Med; 2012 Apr; 9(4):970-85. PubMed ID: 22304626
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of phosphodiesterase type 5 (PDE5) inhibitors in treating erectile dysfunction after bilateral nerve-sparing radical prostatectomy.
Cui Y; Liu X; Shi L; Gao Z
Andrologia; 2016 Feb; 48(1):20-8. PubMed ID: 25684196
[TBL] [Abstract][Full Text] [Related]
10. Nebivolol potentiates the efficacy of PDE5 inhibitors to relax corpus cavernosum and penile arteries from diabetic patients by enhancing the NO/cGMP pathway.
Martínez-Salamanca JI; La Fuente JM; Cardoso J; Fernández A; Cuevas P; Wright HM; Angulo J
J Sex Med; 2014 May; 11(5):1182-92. PubMed ID: 24877179
[TBL] [Abstract][Full Text] [Related]
11. Adherence to initial PDE-5 inhibitor treatment: randomized open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients with erectile dysfunction.
Buvat J; Büttner H; Hatzimouratidis K; Vendeira PA; Moncada I; Boehmer M; Henneges C; Boess FG
J Sex Med; 2013 Jun; 10(6):1592-602. PubMed ID: 23551622
[TBL] [Abstract][Full Text] [Related]
12. Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors.
Tolrà JR; Campaña JMC; Ciutat LF; Miranda EF
J Sex Med; 2006 Sep; 3(5):901-909. PubMed ID: 16942534
[TBL] [Abstract][Full Text] [Related]
13. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction.
Mulhall JP; McLaughlin TP; Harnett JP; Scott B; Burhani S; Russell D
J Sex Med; 2005 Nov; 2(6):848-55. PubMed ID: 16422809
[TBL] [Abstract][Full Text] [Related]
14. Effect of the phosphodiesterase 5 inhibitors sildenafil, tadalafil and vardenafil on rat anococcygeus muscle: functional and biochemical aspects.
Toque HA; Priviero FB; Zemse SM; Antunes E; Teixeira CE; Webb RC
Clin Exp Pharmacol Physiol; 2009 Apr; 36(4):358-66. PubMed ID: 18986324
[TBL] [Abstract][Full Text] [Related]
15. Vardenafil improves penile erection in type 2 diabetes mellitus patients with erectile dysfunction: role of tropomyosin.
Zamorano-León JJ; Olivier C; de Las Heras N; Mateos-Cáceres PJ; Brime Menéndez R; Rodríguez-Sierra P; Martín Palacios N; Manso LS; Modrego J; Segura A; Macaya C; López-Farré AJ
J Sex Med; 2013 Dec; 10(12):3110-20. PubMed ID: 24112450
[TBL] [Abstract][Full Text] [Related]
16. Comparing vardenafil and sildenafil in the treatment of men with erectile dysfunction and risk factors for cardiovascular disease: a randomized, double-blind, pooled crossover study.
Rubio-Aurioles E; Porst H; Eardley I; Goldstein I
J Sex Med; 2006 Nov; 3(6):1037-1049. PubMed ID: 17100937
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the first intake of vardenafil and tadalafil in patients with diabetic neuropathy and diabetic erectile dysfunction.
Kamenov ZA
J Sex Med; 2011 Mar; 8(3):851-64. PubMed ID: 21143421
[TBL] [Abstract][Full Text] [Related]
18. Tadalafil once daily in men with erectile dysfunction: an integrated analysis of data obtained from 1913 patients from six randomized, double-blind, placebo-controlled, clinical studies.
Porst H; Gacci M; Büttner H; Henneges C; Boess F
Eur Urol; 2014 Feb; 65(2):455-64. PubMed ID: 24119319
[TBL] [Abstract][Full Text] [Related]
19. A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunction.
Rubio-Aurioles E; Porst H; Kim ED; Montorsi F; Hackett G; Morales AM; Stuckey B; Būttner H; West TM; Huynh NN; Lenero E; Burns P; Kopernicky V
J Sex Med; 2012 May; 9(5):1418-29. PubMed ID: 22429760
[TBL] [Abstract][Full Text] [Related]
20. A comparison of different oral therapies versus no treatment for erectile dysfunction in 196 radical nerve-sparing radical prostatectomy patients.
Natali A; Masieri L; Lanciotti M; Giancane S; Vignolini G; Carini M; Serni S
Int J Impot Res; 2015; 27(1):1-5. PubMed ID: 25056808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
